store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mithramycin A (Plicamycin) 是一种dna 结合的抗肿瘤抗生素,选择性特异性蛋白1 (Sp1)抑制剂,通过降低Sp1蛋白抑制多种肿瘤的生长。特异性蛋白1 (Sp1)是一种锌指转录因子,调节多种细胞功能,促进肿瘤进展。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 995 | 现货 | ||
5 mg | ¥ 3,370 | 现货 | ||
10 mg | ¥ 4,890 | 现货 | ||
25 mg | ¥ 7,690 | 现货 | ||
50 mg | 特惠询价 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,630 | 现货 |
产品描述 | Mithramycin A (Plicamycin), a DNA-binding antitumor antibiotic, is a selective specificity protein 1 (Sp1) inhibitor, which inhibits the growth of various cancers by decreasing Sp1 protein. Specificity protein 1 (Sp1) is a zinc-finger transcription factor that regulates multiple cellular functions and promotes tumor progression. |
体外活性 | Mithramycin A decreases Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. Mithramycin A inhibits HEp-2 (50, 100, 200nM) and KB cell (20, 40, 80nM) growth in a concentration-dependent manner after 48 h. Apoptotic cell death is qualitatively estimated by DAPI staining for nuclear condensation and fragmentation. Mithramycin A leads to significant DNA fragmentation compared to untreated controls [1]. |
体内活性 | The antitumor activity of Mithramycin A (0.2mg/kg/day) was measured in a xenograft model and the reduction in tumor volume and weight was observed. No significant weight loss was observed in mice treated with Mithramycin A, suggesting that Mithramycin A-associated toxicity was minimal. Mithramycin A also increased TUNEL positive cells in tumor xenografts. No significant intergroup differences were observed in the organs, suggesting no significant signs of systemic toxicity at the dose of Mithramycin A used in this study [1]. |
别名 | Plicamycin |
分子量 | 1085.15 |
分子式 | C52H76O24 |
CAS No. | 18378-89-7 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (82.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 0.9215 mL | 4.6077 mL | 9.2153 mL | 23.0383 mL |
5 mM | 0.1843 mL | 0.9215 mL | 1.8431 mL | 4.6077 mL | |
10 mM | 0.0922 mL | 0.4608 mL | 0.9215 mL | 2.3038 mL | |
20 mM | 0.0461 mL | 0.2304 mL | 0.4608 mL | 1.1519 mL | |
50 mM | 0.0184 mL | 0.0922 mL | 0.1843 mL | 0.4608 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Mithramycin A 18378-89-7 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis Plicamycin Inhibitor inhibitor inhibit